Search results

165 results

Sorted by Relevance . Sort by Date

Guidance Remove Guidance filter
Proposed Remove Proposed filter
In consultation Remove In consultation filter
Technology appraisal guidance Remove Technology appraisal guidance filter
Highly specialised technologies guidance Remove Highly specialised technologies guidance filter
NICE guidelines Remove NICE guidelines filter
Interventional procedures guidance Remove Interventional procedures guidance filter
Social care guidelines Remove Social care guidelines filter

Selumetinib for treating inoperable plexiform neurofibromas associated with type 1 neurofibromatosis in children aged 3 years and over [ID1590]

Proposed [GID-TA10535] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Romosozumab for treating severe osteoporosis [ID3936]

Proposed [GID-TA10828] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Atezolizumab with chemotherapy for neoadjuvant and adjuvant treatment of resectable non-small-cell lung cancer [ID3894]

Proposed [GID-TA10777] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Tirzepatide for treating type 2 diabetes ID3938

Proposed [GID-TA10835] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Sacituzumab govitecan for treating metastatic or unresectable triple-negative breast cancer after 2 or more therapies ID3942

Proposed [GID-TA10829] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Cabozantinib with atezolizumab for untreated advanced hepatocellular carcinoma ID3940

Proposed [GID-TA10830] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Loncastuximab tesirine for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic therapies ID3943

Proposed [GID-TA10831] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Maralixibat for treating cholestatic disease in Alagille Syndrome ID3941

Proposed [GID-TA10832] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Mavorixafor for treating WHIM syndrome ID3946

Proposed [GID-TA10833] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Setmelanotide for treating obesity and hyperphagia in Bardet-Biedl syndrome or Alström syndrome ID3947

Proposed [GID-TA10834] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Gefapixant for treating refractory or unexplained chronic cough [ID3789]

Proposed [GID-TA10678] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Foslevodopa-foscarbidopa for treating Parkinson's disease with motor fluctuations [ID3876]

Proposed [GID-TA10772] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Risankizumab for previously treated active psoriatic arthritis [ID1399]

Proposed [GID-TA10819] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Finerenone for treating chronic kidney disease in people with type 2 diabetes [ID3773]

Proposed [GID-TA10820] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Lifileucel for previously treated unresectable or metastatic melanoma [ID3863]

Proposed [GID-TA10752] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed

Filter (8 in use)

Type 1 selected

Status 2 selected

Last updated

Guidance programme 5 selected

165 results

Selumetinib for treating inoperable plexiform neurofibromas associated with type 1 neurofibromatosis in children aged 3 years and over [ID1590]

Romosozumab for treating severe osteoporosis [ID3936]

Atezolizumab with chemotherapy for neoadjuvant and adjuvant treatment of resectable non-small-cell lung cancer [ID3894]

Tirzepatide for treating type 2 diabetes ID3938

Sacituzumab govitecan for treating metastatic or unresectable triple-negative breast cancer after 2 or more therapies ID3942

Cabozantinib with atezolizumab for untreated advanced hepatocellular carcinoma ID3940

Loncastuximab tesirine for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic therapies ID3943

Maralixibat for treating cholestatic disease in Alagille Syndrome ID3941

Mavorixafor for treating WHIM syndrome ID3946

Setmelanotide for treating obesity and hyperphagia in Bardet-Biedl syndrome or Alström syndrome ID3947

Gefapixant for treating refractory or unexplained chronic cough [ID3789]

Foslevodopa-foscarbidopa for treating Parkinson's disease with motor fluctuations [ID3876]

Risankizumab for previously treated active psoriatic arthritis [ID1399]

Finerenone for treating chronic kidney disease in people with type 2 diabetes [ID3773]

Lifileucel for previously treated unresectable or metastatic melanoma [ID3863]